TSLA *BANG* incoming (bullet in the chamber rn)

I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’s promise, and a secret Elon project set to revolutionize a $23 Trillion market…

Click here to review Tim’s special Holiday offer before it’s too late.

Andrew Sinclair Biography and Net Worth

Director of Adicet Bio

Andrew Sinclair is on the board of Sierra Oncology, Inc., Soleno Therapeutics, Inc., Verona Pharma Plc and Adicet Bio, Inc. and Portfolio Manager & Partner at Abingworth Management Ltd. and Member of Institute of Chartered Accountants in England & Wales.

In the past Dr. Sinclair held the position of Research Analyst at Credit Suisse Securities (Europe) Ltd. and Research Analyst at HSBC Bank Plc (Broker).

He received an undergraduate degree from King's College London.

How do I contact Andrew Sinclair?: The corporate mailing address for Mr. Sinclair and other Adicet Bio executives is 4 TRI HARBOR COURT, PORT WASHINGTON NY, 11050. Adicet Bio can also be reached via phone at (650) 503-9095 and via email at [email protected]. Learn More on Andrew Sinclair's contact information.
Has Andrew Sinclair been buying or selling shares of Adicet Bio?: Andrew Sinclair has not been actively trading shares of Adicet Bio within the last three months. Most recently, on Wednesday, December 8th, Andrew Sinclair bought 500,000 shares of Adicet Bio stock. The stock was acquired at an average cost of $14.00 per share, with a total value of $7,000,000.00. Learn More on Andrew Sinclair's trading history.
Who are Adicet Bio's active insiders?: Adicet Bio's insider roster includes Chen BA (), Jay Elliott (COO), Aya Jakobovits (Director), Chen Schor (CEO), and Andrew Sinclair (Director). Learn More on Adicet Bio's active insiders.
Are insiders buying or selling shares of Adicet Bio?: In the last twelve months, Adicet Bio insiders bought shares 1 times. They purchased a total of 3,125,000 shares worth more than $7,500,000.00. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 5,900 shares worth more than $8,437.00. The most recent insider tranaction occured on June, 5th when Director Michael Kauffman sold 5,900 shares worth more than $8,437.00. Insiders at Adicet Bio own 19.1% of the company. Learn More about insider trades at Adicet Bio.
Information on this page was last updated on 6/5/2024.

Andrew Sinclair Insider Trading History at Adicet Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/8/2021	Buy	500,000	$14.00	$7,000,000.00

Andrew Sinclair Buying and Selling Activity at Adicet Bio

Adicet Bio Company Overview

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

Today's Range

Now: $0.91

$0.91

$0.98

50 Day Range

MA: $1.12

$0.86

$1.52

2 Week Range

Now: $0.91

$0.81

$3.77

Volume

141,403 shs

Average Volume

1,066,457 shs

Market Capitalization

$75.19 million

P/E Ratio

N/A

Dividend Yield